Can gene editing help with hereditary eye diseases? A new study explores the possibility
Gene editing technique developed in Switzerland shows promise in curing Stargardt disease, a rare genetic eye disease causing ...
Benchmark sees growth for Belite Bio shares, highlights Tinlarebant's promise in rare diseases
Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous ...
Benchmark Co. Keeps Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Belite Bio, Inc. ADR (BLTE – Research Report) today and set a price target of ...
Belite Bio price target raised to $79 from $57 at Benchmark
Benchmark raised the firm’s price target on Belite Bio (BLTE) to $79 from $57 and keeps a Buy rating on the shares. After speaking to ...